Elevai Biosciences, a Subsidiary of Elevai Labs (ELAB), Expands Patent Portfolio

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. JNJ
2. SNDX
3. HUM
4. META
5. OIG
6. AMAT
7. FBK
8. HCLT:IN
9. SPY
10. DMART:IN

Go back to Elevai Biosciences, a Subsidiary of Elevai Labs (ELAB), Expands Patent Portfolio

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

October 3, 2024 7:30 AM EDT

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets

NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the filing of two novel patent applications for... More